Gilead Sciences announces deal to manufacture generic versions of lenacapavir, but critics say it excludes many countries where incidence is highest
Cheaper versions of the “gamechanger” HIV prevention drug lenacapavir are to be made available in 120 low- and middle-income countries, manufacturer Gilead Sciences has announced.
However, campaigners said the deal “abandons” many countries with a high HIV burden, particularly in Latin America, and urged transparency over exact pricing.
More Stories
Europe must boost space investment to secure autonomy from US, says ESA boss
Revealed: Chinese researchers can access half a million UK GP records
US food delivery app DoorDash offers to buy UK rival Deliveroo for $3.6bn